Skip to main content

Update On Hematopathology Classification: The International Consensus Classification Perspective

Original release date:
November 17, 2023
Access to this course expires on:  October 14, 2026 at 11:59 PM Pacific Time
CME 24.25

Course Description
The diagnosis and classification of hematopoietic tumors is increasingly complex and evolves rapidly. The introduction of the International Consensus Classification (ICC) of Myeloid and Lymphoid Neoplasms and publication of the proposed 5th edition World Health Organization (WHO) classification of the same tumors is the latest stage in this evolution and both further expand the clinical, morphologic, immunophenotypic and molecular genetic criteria for diagnosis. Join USCAP and learn from developers of the ICC on what is new in the classification of these tumors and how the ICC and proposed WHO compare. Leading clinical experts in hematology/oncology will also provide clinician perspectives on the importance of proper disease classification. The course will include disease specific lectures as well as opportunities to join experts in interactive microscopy sessions to gain practical knowledge on how to implement the new disease classifications into practice.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Familiarize the attendee with the process for developing the International Consensus Classification of Myeloid and Lymphoid Neoplasms
  • Discuss diagnostic criteria for major hematopoietic tumor disease categories
  • Learn how to implement molecular genetic testing into the diagnosis and classification of hematologic neoplasms

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 24.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Daniel A. Arber, MD, James R. Cook, MD, Adam Bagg, MD, Michael J. Borowitz, MD, Katherine R. Calvo, MD, Elias Campo, MD, John R. Goodlad, MD, MBChB, FRCPath, Robert Hasserjian, MD, Steven Horwitz, MD, Elaine S. Jaffe, MD, Rebecca L. King, MD, Hans Michael Kvasnicka, MD, PhD, Olatoyosi Odenike, MD, Attilio Orazi, MD, FRCPath, Leticia Quintanilla-Fend, MD, Ayalew Tefferi, MD, Sa A. Wang, MD, Jane Winter, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. Learners can now self-submit CME on all earned certificates. View and print your certificates by clicking here.

USCAP members receive a discount on all e-Learning courses. Not A Member? Click Here to sign up today.